Can CombiPatch Cause Weight Loss? Honest Evidence Review

At a glance

• CombiPatch is FDA-approved for menopausal vasomotor symptoms, vulvovaginal atrophy, and hypoestrogenism — not weight loss. The label states it is indicated “in a woman with a uterus for treatment of moderate to severe vasomotor symptoms due to menopause”^[1].
• The Cochrane HRT-and-weight systematic review found no evidence that hormone therapy causes weight gain and no evidence it produces clinically meaningful weight loss either — the pooled effect across randomized trials is essentially zero^[2].
• The CombiPatch FDA label lists “weight increased” (not decreased) as a post-marketing miscellaneous adverse reaction alongside angioedema and hypersensitivity^[1]. Weight loss is not a labeled adverse reaction at any frequency in the Table 9 clinical-trial dataset.
• Transient fluid changes are possible. Estrogen can produce modest sodium and water retention in the first 1–3 months; the progestin component (norethindrone) can do the same. These are water-weight shifts, not fat changes, and typically stabilize.
• Menopausal weight gain is real but largely age-related. The SWAN cohort showed visceral fat increases and resting energy expenditure decreases across the menopausal transition; HRT does not drive these changes and may modestly attenuate the shift toward central adiposity^[4].
• If weight loss is the goal, HRT is the wrong tool. The evidence-based pharmacotherapies for chronic weight management are GLP-1 receptor agonists (semaglutide, tirzepatide) with magnitudes that dwarf any HRT signal^[6][7].
• HRT and a GLP-1 can be combined when both indications exist. CombiPatch treats menopausal symptoms; the GLP-1 treats obesity. Decisions belong with the prescribing clinician, not a single-drug substitution.

What CombiPatch actually is

CombiPatch is a twice-weekly transdermal patch that delivers two hormones simultaneously through the skin. Per the FDA-approved DailyMed label, it is “an adhesive-based matrix transdermal patch designed to release both estradiol, an estrogen, and norethindrone acetate (NETA), a progestational agent, continuously upon application to intact skin.”^[1] Two strengths are available: 0.05 mg estradiol / 0.14 mg NETA per day and 0.05 mg estradiol / 0.25 mg NETA per day.

The label's FDA-approved indications, quoted verbatim from the DailyMed prescribing information, are:

1. “Treatment of moderate to severe vasomotor symptoms due to menopause.”
2. “Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause.”
3. “Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure.”^[1]

Weight management is not a listed indication, and the label does not assert any weight-related benefit anywhere in the Indications and Usage or Clinical Studies sections.

What the CombiPatch FDA label actually says about weight

The clinical-trial Adverse Reactions table (Table 9 in the DailyMed label) reports adverse reactions occurring at a frequency of 5 percent or greater on either CombiPatch formulation during the pivotal vasomotor-symptom and endometrial-protection studies. Weight change does not appear in Table 9 at any frequency at or above the 5 percent threshold. The most common adverse reactions on the 0.05/0.14 mg per day strength versus placebo were headache (18% vs 20%), back pain (11% vs 5%), nausea (11% vs 7%), and breast pain (17% on combined treatment, frequency varies by strength)^[1].

Where weight does appear is in the post-marketing surveillance section, in the “Miscellaneous” category, which lists verbatim: “Angioedema, hypersensitivity, weight increased.”^[1] “Weight decreased” is not listed as a post-marketing adverse reaction. The direction of the post-marketing signal, to the extent there is one, is toward weight gain, not loss.

This pattern is consistent with how every combined-HRT label we've audited handles weight: labeled as a non-quantified post-marketing event, never as an indication, never with a magnitude. If a patient is taking CombiPatch and losing meaningful weight, the FDA label does not predict that outcome and does not provide a mechanism for it.

The Cochrane HRT-and-weight systematic review

The most rigorous synthesis of this question is the Cochrane review by Norman, Flight, and Rees: Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution, published in the Cochrane Database of Systematic Reviews in 2000^[2].

The review pooled randomized controlled trials comparing unopposed estrogen or combined estrogen-plus-progestogen HRT against placebo (or against no treatment) in peri- and post-menopausal women, with weight or body composition as a prespecified outcome. The authors' conclusion was clear: there was no evidence that HRT causes weight gain in peri- or post-menopausal women, and no evidence of a clinically significant difference in weight between HRT-treated and placebo-treated participants. The corresponding author conclusion is the foundation cited by subsequent position statements when patients ask whether HRT will make them gain weight.

The corollary, which is the question this article is about, is equally clean: HRT also does not produce clinically meaningful weight loss. The pooled net effect across the trials is approximately zero in either direction. A drug that does not produce weight gain at the population level cannot, by the same statistical logic, be relied on to produce weight loss.

The 2012 Climacteric review by Davis and colleagues, written for World Menopause Day on behalf of the International Menopause Society, reached the same conclusion in updated language: midlife weight gain is “largely related to environmental and lifestyle factors” and the menopausal transition itself, not to HRT use, and HRT “has no demonstrable effect on body weight in the majority of women”^[3].

Why some women report weight changes on CombiPatch (the fluid shift)

Patient-reported weight changes in the first 1 to 3 months on CombiPatch are real, but they are predominantly fluid shifts rather than fat-mass changes:

• Estrogen and sodium retention. Estradiol modulates the renin-angiotensin-aldosterone axis and can produce modest sodium and water retention, particularly in the first weeks of any new estrogen exposure. The magnitude is small (typically <2 kg) and self-limited.
• Progestin and breast or peripheral fluid changes. Synthetic progestins including norethindrone can produce mild fluid retention, breast tenderness, and bloating in some users. These also tend to attenuate over the first 1 to 3 months.
• Menopause itself is a moving baseline. The SWAN longitudinal cohort showed an average increase of roughly 1.7 kg of fat mass and a measurable decline in resting energy expenditure across the menopausal transition, independent of HRT use^[4]. Women starting HRT in their late forties or early fifties are simultaneously progressing through a transition that, on its own, predisposes to modest weight gain.

The honest framing for a patient: if you gain 1 to 2 kg in your first month on CombiPatch, the most likely explanation is fluid retention plus the underlying age-and-menopause trajectory; if the same patient loses 1 to 2 kg, the most likely explanation is lifestyle change or the natural inter-week variability of body weight, not a pharmacologic effect of the patch.

Estrogen and body fat distribution: where HRT may matter

The one place where HRT does measurably interact with body composition is the distribution of body fat, not the total amount. The Lovejoy 2008 SWAN cohort analysis followed 156 women across the menopausal transition with serial DXA and indirect calorimetry. Across the transition, women showed a statistically significant increase in visceral adipose tissue and a decline in fat-free mass and resting metabolic rate, independent of total weight change^[4].

The Davis 2012 review and subsequent literature have argued that combined HRT may attenuate this menopause-associated shift toward central adiposity by maintaining the premenopausal estradiol environment that favors gluteofemoral over abdominal fat storage^[3]. The size of this attenuation is modest, the data are observational and inconsistent across studies, and crucially the net effect on total body weight remains close to zero. HRT is not, in any defensible reading of the evidence, a fat-loss intervention.

Norethindrone (the progestin) and weight

Patients sometimes single out the progestin component of combined HRT as the suspected cause of weight gain. The evidence does not support this for norethindrone in the CombiPatch dose range. The Davis 2012 review surveyed the comparative literature and concluded that the choice of progestin within a combined-HRT regimen has minimal consistent effect on body weight at the doses used for endometrial protection^[3]. Patient-reported “the progestin made me gain weight” experiences are real, but the randomized data show those changes are not pharmacologically large and are dominated by fluid effects in the first weeks rather than fat accumulation over months.

CombiPatch and GLP-1 medications: the clinical pathway for menopause + obesity

For women who present with both menopausal vasomotor symptoms and obesity, the two conditions are treated separately by drugs with their own indications:

• CombiPatch (or another HRT regimen) for the menopausal symptoms and bone-density indication, per the NAMS 2022 position statement which supports HRT for symptomatic women under 60 or within 10 years of menopause onset when benefits outweigh risks^[5].
• A GLP-1 receptor agonist (Wegovy, Zepbound, or Saxenda) for chronic weight management when BMI thresholds and clinical criteria are met. Magnitudes from the pivotal trials are −14.9% total body weight on semaglutide 2.4 mg over 68 weeks^[6] and −20.9% on tirzepatide 15 mg over 72 weeks^[7] — orders of magnitude beyond anything HRT produces.

For a deeper review of the HRT-and-GLP-1 interaction including bone-density, sleep, and vasomotor-symptom considerations, see our GLP-1 + HRT menopause evidence review and the perimenopause HRT + GLP-1 article. The hormonal-cycle context for GLP-1 users is covered in our GLP-1 and the menstrual cycle deep-dive.

When CombiPatch is the right call (menopausal symptoms, not weight)

The 2022 hormone-therapy position statement of the North American Menopause Society^[5] is the current authoritative guidance for HRT prescribing. NAMS recommends HRT, including transdermal combination products like CombiPatch, as first-line treatment for moderate to severe vasomotor symptoms in symptomatic women under 60 years of age or within 10 years of menopause onset, when there are no contraindications and benefits are judged to outweigh risks. The statement also supports HRT use for prevention of bone loss in symptomatic women at elevated fracture risk.

Weight loss is not on the list of NAMS-supported indications. Anywhere CombiPatch is prescribed appropriately, the goal is symptom relief or bone protection — not a number on the scale.

Alternatives to CombiPatch if weight is your main concern

If a patient's primary clinical goal is weight reduction rather than menopausal-symptom management, HRT is not the right intervention and the FDA label does not support that off-label use. The evidence-based options for chronic weight management are:

• GLP-1 receptor agonists. Semaglutide 2.4 mg weekly (Wegovy) produced −14.9% total body weight loss versus −2.4% on placebo over 68 weeks in STEP-1^[6]. Tirzepatide 15 mg weekly (Zepbound) produced −20.9% versus −3.1% over 72 weeks in SURMOUNT-1^[7]. Liraglutide 3 mg daily (Saxenda) is a daily option with a smaller magnitude (~−5 to −8%).
• Comprehensive lifestyle intervention. Structured diet plus physical activity remains the foundation and the comparator arm in every weight-loss pharmacotherapy trial.
• Metabolic and bariatric surgery for appropriately selected patients at higher BMI thresholds.

These options are independent of menopausal status. Both decisions — whether to start HRT for menopausal symptoms and whether to start a weight-loss medication for obesity — belong with the prescribing clinician, who can evaluate them on their own indications without one being forced to do the work of the other.

Verdict

CombiPatch does not cause weight loss. The FDA-approved label does not list it as an indication, does not include weight decrease in the clinical-trial Adverse Reactions table, and flags “weight increased” (not decreased) in the post-marketing miscellaneous adverse-reaction list^[1]. The Cochrane HRT-and-weight systematic review found essentially zero net effect of combined hormone therapy on body weight versus placebo^[2], and the 2012 Climacteric review concluded HRT “has no demonstrable effect on body weight in the majority of women”^[3].

Transient water-weight shifts in the first 1 to 3 months are real but small and self-limited. Menopausal weight gain is also real, but it is driven by aging and the menopausal transition itself, not by HRT use. For women whose primary clinical goal is weight reduction, the evidence-based options are GLP-1 receptor agonists with magnitudes that dwarf anything HRT produces in either direction^[6][7]. CombiPatch and a GLP-1 can coexist when both indications are present, but neither should be substituted for the other.

This article is educational and does not constitute medical advice. Decisions about CombiPatch, other hormone-therapy products, and weight-loss pharmacotherapy should be made with the prescribing clinician. CombiPatch is FDA-approved for menopausal symptoms and hypoestrogenism, not for weight loss; off-label use for weight management is not supported by the label or by systematic evidence.